中信建投证券研报称，近期，部分脑机接口企业升级产品通道数，或计划提交三类证注册申报。预计国 家及各地政府对脑机接口产业的支持政策将持续推出，在多重政策强力支持下，临床和商业化落地有望 提速，投资机会将逐步增多。今年以来脑机接口相关上市公司估值提升，有望带动一级市场融资热度及 相关公司估值重构，资本和产业发展形成共振，建议关注自研能力较强或与头部高校院所有深度合作的 标的，或与知名脑机接口一级市场企业有投资入股或深度合作的标的。 ...

钛媒体App 12月9日消息，中信建投研报称，近期，部分脑机接口企业升级产品通道数，或计划提交三 类证注册申报。预计国家及各地政府对脑机接口产业的支持政策将持续推出，在多重政策强力支持下， 临床和商业化落地有望提速，投资机会将逐步增多。今年以来脑机接口相关上市公司估值提升，有望带 动一级市场融资热度及相关公司估值重构，资本和产业发展形成共振，建议关注自研能力较强或与头部 高校院所有深度合作的标的，或与知名脑机接口一级市场企业有投资入股或深度合作的标的。（广角观 察） ...

智通财经APP获悉，中信建投发布研究报告称，央行购金，是近年分析金价绕不开的变量。相较市场化 的ETF等行为，央行购金数据透明度低，增加了黄金研究的难点。本轮央行购金伴随着一些别样特征， 例如多国央行更倾向于国内购金，也更偏好境内存储，说明本轮央行购金的底层动机并非简单的外汇头 寸市场化管理，更顺应货币秩序重塑大势。 看清这一点之后，可以得到两点结论： 第一，央行购金并不是每一次金价上涨的驱动力，但央行购金可为黄金价格中枢提供支撑。 第二，金价长期上涨的叙事，需要警惕一次大逆转，即新老货币秩序完成交替。旧有货币体系失序终将 收敛，届时黄金将进入大周期的另一侧。只不过从当下看，完成货币秩序重塑需要时间。 中信建投主要观点如下： 2025年最优的大类资产是贵金属，金和银。 对黄金的讨论热潮空前。在市场化因素背后，有一个黄金做多的"买手"被越来越多人关注——央行购 金。 央行购金大部分并非为了直接交易。 客观来说，2022年至今多国央行购金比例发生明显跃升，这反映了怎样的央行动机，并映射了怎样的宏 观趋势?未来央行购金如何演绎，如何影响黄金价格?这些问题是当前黄金研究的热点话题。 一、央行购金，首先需要排除一些朴素 ...

中信建投指出，在行业扩产整体放缓大背景下，我们认为国产化驱动下的渗透率提升依然是设备板块后 续增长的重要来源。我们判断未来设备国产化率将实现快速提升，头部整机设备企业 2025 年订单有望 实现 20-30%以上增长，零部件、尤其是卡脖子零部件国产化进程有望加快，板块整体基本面向好。景 气度方面，预计2025年前道CAPEX仍有增长，先进制程维持较强表现，成熟制程复苏；后道封装温和 复苏，2.5D/3D先进封装下半年有望有积极进展。 (本文来自第一财经) ...

中信建投研报称，近期，部分脑机接口企业升级产品通道数，或计划提交三类证注册申报。预计国家及 各地政府对脑机接口产业的支持政策将持续推出，在多重政策强力支持下，临床和商业化落地有望提 速，投资机会将逐步增多。今年以来脑机接口相关上市公司估值提升，有望带动一级市场融资热度及相 关公司估值重构，资本和产业发展形成共振，建议关注自研能力较强或与头部高校院所有深度合作的标 的，或与知名脑机接口一级市场企业有投资入股或深度合作的标的。 （文章来源：第一财经） ...

证券日报网讯 12月8日，中信建投在互动平台回答投资者提问时表示，根据2025年第三季度报告，截至 2025年9月末公司普通股股东总数为118395户。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 12月8日，中信建投在互动平台回答投资者提问时表示，上市公司股价波动受宏观经济、 行业、市场等多重因素影响，可能出现阶段性上涨或者下跌。公司始终坚持稳健发展，2025年前三季度 实现营业收入172.89亿元，同比增长31.25%，实现归母净利润70.89亿元，同比增长64.95%，收入利润 位于境内上市券商前十名。公司将继续聚焦主责主业深耕经营，努力提升内在价值，致力于为股东提供 更好回报。 ...

Core Viewpoint - The pharmaceutical sector in China is entering a critical phase characterized by "innovation realization and global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] Group 1: Market Performance - The A-share pharmaceutical sector experienced a slight increase, with the CSI 300 Healthcare Index rising by 0.3%, the CSI Innovative Drug Industry Index up by 0.2%, and the CSI Biotechnology Theme Index increasing by 0.04% [1] - In contrast, the Hong Kong pharmaceutical sector saw a broad decline, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index falling by 1.8% and the CSI Hong Kong Stock Connect Healthcare Comprehensive Index decreasing by 1.4% [1] - Despite the downturn in Hong Kong, there was a significant net subscription of nearly 20 million units for the Hang Seng Innovative Drug ETF (159316) throughout the day [1] Group 2: Industry Outlook - CITIC Securities indicates that the Chinese pharmaceutical industry is focusing on innovation commercialization, global breakthroughs, policy optimization, and opportunities arising from industry mergers and acquisitions by 2026 [1] - Companies are actively exploring diversified overseas expansion paths to enhance their market presence [1]

Core Viewpoint - The report from CITIC Securities highlights that Yangguang Electric achieved record-high performance in Q3 2025, driven by global energy storage demand and an increase in high-margin overseas business [1] Financial Performance - In Q3 2025, Yangguang Electric reported operating revenue of 22.869 billion yuan, a year-on-year increase of 20.83% and a quarter-on-quarter decrease of 6.65% [1] - The net profit attributable to shareholders reached 4.147 billion yuan, reflecting a year-on-year increase of 57.04% and a quarter-on-quarter increase of 6.10% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 3.991 billion yuan, with a year-on-year increase of 59.76% and a quarter-on-quarter increase of 4.50% [1] Future Outlook - The global demand for energy storage is expected to continue to resonate, driving rapid growth in the company's energy storage shipments [1] - The AIDC配储 orders and the gradual rollout of power products are anticipated to further contribute to profit growth for the company [1] - The company maintains a "Buy" rating based on these positive indicators [1]

Market Overview - The Hong Kong stock market faced pressure, with the Hang Seng Index dropping over 1%, closing at 25,965.36 points, down 1.23% or 319.72 points, with a total turnover of HKD 2,062.3 million [1] - The Hang Seng China Enterprises Index fell by 1.25% to 9,083.53 points, while the Hang Seng Tech Index remained flat at 5,662.55 points [1] Blue Chip Performance - Baidu Group-SW (09888) led blue-chip stocks, rising 3.45% to HKD 125.8, contributing 8.38 points to the Hang Seng Index [2] - Other notable performers included SMIC (00981) up 2.94%, China Ping An (02318) up 2.15%, while China Construction Bank (00939) fell 4.01%, dragging the index down by 54.39 points [2] Sector Highlights - Large tech stocks generally declined, with Alibaba down over 1% and Tencent down 0.82% [3] - Chinese brokerage stocks rose against the trend, with Huatai Securities (06886) up 5.17% and GF Securities (01776) up 3.1% [3] - The light communication sector saw significant gains, with Huiju Technology rising over 7% [4] - Lithium stocks mostly increased, with Ganfeng Lithium (01772) up 6.95% and CATL (03750) up 3.28% [5] Regulatory Developments - The Chairman of the China Securities Regulatory Commission (CSRC) emphasized the need to accelerate the development of top-tier investment banks and institutions, indicating a potential easing of regulations for quality institutions [4] - The CSRC plans to optimize risk control indicators and moderately open up capital space and leverage limits, which could benefit leading brokerages [4] New Listings and Stock Movements - Two new stocks were listed, with Zhuoyue Ruixin (02687) surging 87.26% and Naxinwei (02676) declining 4.31% [7] - Restructured Energy (02570) faced a significant drop of 27.33% on its first trading day after the lock-up period ended [8] - Silver Pharma-B (02591) saw a decline of 14.32% following its inclusion in the Hong Kong Stock Connect [9] - Sutech (02498) performed well, rising 5.23% after securing a major order from FAW Toyota [10] Pharmaceutical Sector Updates - The National Healthcare Security Administration announced the addition of 114 new drugs to the 2025 National Medical Insurance Drug List, with a success rate of 88%, up from 76% in 2024 [6]